article thumbnail

Utilization of Treatment for Chlamydia and Gonorrhea in the Primary Care Setting Using the American Family Cohort [Infectious diseases (not respiratory tract)]

Annals of Family Medicine

Since untreated cases can have severe health consequences, non-adherence to the Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment guidelines (CDC) remains a concern. Study Design and Analysis: A retrospective cohort from 2018-2022. treatment rates, respectively.

article thumbnail

Development of a Multidisciplinary Clinic for the Treatment of Obesity in a Canadian University Family Medicine Group (U-FMG) [Obesity, exercise and nutrition]

Annals of Family Medicine

Context In 2018, 63.1% Population Studied Patients with obesity enrolled in the Méta-Santé clinic. Setting The North of Lanaudière University Family Medicine Group (U-FMG) Intervention Upon referral from their family doctor, patients attend a group course on nutrition and metabolic health.

DO 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Treatment of Chlamydia and Gonorrhea in Primary Care and Its Patient-Level Variation: An American Family Cohort Study [Original Research]

Annals of Family Medicine

Nonadherence to the Centers for Disease Control and Prevention treatment guidelines remains a concern. METHODS We used electronic health records from the PRIME registry to identify patients with diagnosis codes or positive test results for chlamydia and/or gonorrhea from 2018 to 2022. of these cases, respectively, were treated.

article thumbnail

Comorbidities Influence Optic Outcomes in NMOSD

Physician's Weekly

Data was collected from 22 centers across North and South America, Asia, and Europe, following STROBE reporting guidelines. The dataset, acquired between 2000 and 2018, comprised OCT and clinical metadata. The AQP4-NMOSD individuals with CVC/RF had higher ON relapse rates than those with AID (1.06 ± 3.33

article thumbnail

At Long Last, FDA Unveils Plan for Rare Disease Innovation Hub

FDA Law Blog

Peter Marks at James Valentine ’s FDA Rare Disease Town Hall session at the DIA Annual Meeting last month (see Pink Sheet coverage here ), this Hub is intended to serve as the Center of Excellence that we in the rare disease community have been calling for its establishment over the last several years.

article thumbnail

FDA Creates a New Advisory Committee for Genetic Metabolic Diseases – Could This Be an Opportunity to Support Rare Disease Product Development More Broadly?

FDA Law Blog

Janet Maynard, Director of this Office, highlighted in the press release that “[g]enetic metabolic diseases include very rare diseases that individually affect a limited number of patients. Drug development for these conditions has unique and complex challenges, therefore few treatments are available to patients.”

article thumbnail

District Court Interprets EKRA

FDA Law Blog

Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. These lab tests are performed for physicians, substance abuse treatment centers and other types of organizations.